Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) response to corticosteroids and cytotoxic medications appears to be the most important determinant of survival. The purpose of this retrospective study was to analyse the determinants of response to immunosuppressive therapy with prednisone alone, or prednisone and cyclophosphamide, in IPF. Twenty five consecutive patients were studied. Initial evaluation in untreated patients included clinical, biological and functional parameters. Sequential evaluation by pulmonary function tests (forced vital capacity (FVC) and transfer factor of the lungs for carbon monoxide (TLCO)) was performed at a 3 month interval. Response to therapy was defined as an improvement in FVC and/or TLCO of more than 10% after 12 months, with maintenance of this improvement for at least another 12 months. Twelve of the 25 patients were classified as responders. A symptomatic disease of less than 12 months duration before onset of therapy related to response. FVC was more impaired in the group of responders when the comparison was limited to patients with an FVC of less than 90%. Bronchoalveolar lavage cell counts were not significantly different between responders and non-responders. Assessment of pulmonary function after 3 months of treatment was predictive of maintenance of the response or of even further improvement. Patients with improved FVC after 3 months of therapy had a significantly shorter symptomatic disease before onset of treatment (7.6 +/- 7.1 vs 20.2 +/- 18.6 months). A beneficial effect of addition of cyclophosphamide was observed only in patients who demonstrated an early but short-lived improvement to steroids. Adverse reactions of immunosuppressive therapy were noticed in 10 patients, and required discontinuation of treatment in six of them.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				R. M Rudd, R. J Prescott, J C Chalmers, I. D A Johnston, and for the Fibrosing Alveolitis Subcommittee of the R British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival Thorax, January 1, 2007; 62(1): 62 - 66. [Abstract] [Full Text] [PDF]

				F. J. Martinez and K. Flaherty Pulmonary function testing in idiopathic interstitial pneumonias. Proceedings of the ATS, January 1, 2006; 3(4): 315 - 321. [Abstract] [Full Text] [PDF]

				N. Walter, H. R. Collard, and T. E. King Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proceedings of the ATS, January 1, 2006; 3(4): 330 - 338. [Abstract] [Full Text] [PDF]

				D. Bouros and K. M. Antoniou Current and future therapeutic approaches in idiopathic pulmonary fibrosis Eur. Respir. J., October 1, 2005; 26(4): 693 - 703. [Abstract] [Full Text] [PDF]

				G. Raghu, K. K. Brown, W. Z. Bradford, K. Starko, P. W. Noble, D. A. Schwartz, T. E. King Jr., and the Idiopathic Pulmonary Fibrosis Study Group A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis N. Engl. J. Med., January 8, 2004; 350(2): 125 - 133. [Abstract] [Full Text] [PDF]

				K. Watanabe, K. Higuchi, K. Ninomiya, T. Ohshima, T. Aritomi, Y. Kawabata, and M. Yoshida Steroid treatment based on the findings of transbronchial biopsy in idiopathic interstitial pneumonia Eur. Respir. J., November 1, 2002; 20(5): 1213 - 1219. [Abstract] [Full Text] [PDF]

				D. A. Zisman, J. P. Lynch III, G. B. Toews, E. A. Kazerooni, A. Flint, and F. J. Martinez Cyclophosphamide in the Treatment of Idiopathic Pulmonary Fibrosis : A Prospective Study in Patients Who Failed To Respond to Corticosteroids Chest, June 1, 2000; 117(6): 1619 - 1626. [Abstract] [Full Text] [PDF]

				A. YOKOYAMA, N. KOHNO, H. HAMADA, M. SAKATANI, E. UEDA, K. KONDO, Y. HIRASAWA, and K. HIWADA Circulating KL-6 Predicts the Outcome of Rapidly Progressive Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., November 1, 1998; 158(5): 1680 - 1684. [Abstract] [Full Text] [PDF]

				A. XAUBET, C. AGUSTI, P. LUBURICH, J. ROCA, C. MONTON, M. C. AYUSO, J. A. BARBERA, and R. RODRIGUEZ-ROISIN Pulmonary Function Tests and CT Scan in the Management of Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., August 1, 1998; 158(2): 431 - 436. [Abstract] [Full Text] [PDF]

				D. W Mapel, W. C Hunt, R. Utton, K. B Baumgartner, J. M Samet, and D. B Coultas Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts Thorax, June 1, 1998; 53(6): 469 - 476. [Abstract] [Full Text]

				S. E. GAY, E. A. KAZEROONI, G. B. TOEWS, J. P. LYNCH III, B. H. GROSS, P. N. CASCADE, D. L. SPIZARNY, A. FLINT, M. ANTHONY SCHORK, R. I. WHYTE, et al. Idiopathic Pulmonary Fibrosis . Predicting Response to Therapy and Survival Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): 1063 - 1072. [Abstract] [Full Text] [PDF]

				B. T. SOCIETY and S. O. C. COMMITTEE The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults---British Thoracic Society recommendations Thorax, April 1, 1990; 54(90001): 1S - 28. [Full Text]